CL2015003554A1 - Preparado farmacéutico. - Google Patents
Preparado farmacéutico.Info
- Publication number
- CL2015003554A1 CL2015003554A1 CL2015003554A CL2015003554A CL2015003554A1 CL 2015003554 A1 CL2015003554 A1 CL 2015003554A1 CL 2015003554 A CL2015003554 A CL 2015003554A CL 2015003554 A CL2015003554 A CL 2015003554A CL 2015003554 A1 CL2015003554 A1 CL 2015003554A1
- Authority
- CL
- Chile
- Prior art keywords
- solution
- alfa
- radionucclid
- complex
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
MÉTODO PARA GENERAR UNA SOLUCIÓN PURIFICADA DE POR LO MENOS UN RADIONÚCLIDO EMISOR ALFA, QUE COMPRENDE PONER EN CONTACTO UNA SOLUCIÓN QUE COMPRENDE DICHO AL MENOS UN COMPLEJO DE RADIONÚCLIDO EMISOR ALFA Y POR LO MENOS UN NÚCLIDO HIJO QUE TIENE POR LO MENOS UN LIGANTE SELECTIVO PARA DICHO POR LO MENOS UN NÚCLIDO HIJO Y SUBSIGUIENTEMENTE SEPARAR DICHA SOLUCIÓN DE POR LO MENOS UN COMPLEJO DE RADIONÚCLIDO EMISOR ALFA DE DICHO POR LO MENOS UN LIGANTE SELECTIVO; MÉTODO PARA REDUCIR LA RADIÓLISIS DE POR LO MENOS UN COMPONENTE ORGÁNICO EN UNA SOLUCIÓN; MÉTODO PARA LA ELIMINACIÓN DE POR LO MENOS UN RADIONÚCLIDO HIJO DE UNA SOLUCIÓN; CONJUNTO DE ELEMENTOS PARA LA FORMACIÓN DE UN PREPARADO FARMACÉUTICO DE POR LO MENOS UN COMPLEJO DE RADIOISÓTOPO EMISOR ALFA; DISPOSITIVO DE ADMINISTRACIÓN; Y MÉTODO PARA FORMAR UNA SOLUCIÓN INYECTABLE DE UN COMPLEJO CON EL ALFA-RADIONÚCLIDO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015003554A1 true CL2015003554A1 (es) | 2016-07-15 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015003554A CL2015003554A1 (es) | 2013-06-05 | 2015-12-04 | Preparado farmacéutico. |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (es) |
| EP (1) | EP3003401B1 (es) |
| JP (1) | JP6580559B2 (es) |
| KR (1) | KR102321763B1 (es) |
| CN (1) | CN105592863B (es) |
| AP (1) | AP2015008894A0 (es) |
| AU (1) | AU2014276885B2 (es) |
| BR (1) | BR112015030298A2 (es) |
| CA (1) | CA2914278C (es) |
| CL (1) | CL2015003554A1 (es) |
| CR (1) | CR20150642A (es) |
| CU (1) | CU24535B1 (es) |
| DK (1) | DK3003401T3 (es) |
| DO (1) | DOP2015000294A (es) |
| EA (1) | EA201501174A1 (es) |
| ES (1) | ES2782624T3 (es) |
| GB (1) | GB201310028D0 (es) |
| HR (1) | HRP20200456T1 (es) |
| IL (1) | IL242704B (es) |
| LT (1) | LT3003401T (es) |
| MA (1) | MA38650B1 (es) |
| MX (1) | MX366028B (es) |
| MY (1) | MY180717A (es) |
| NI (1) | NI201500173A (es) |
| PE (1) | PE20160215A1 (es) |
| PH (1) | PH12015502715B1 (es) |
| PL (1) | PL3003401T3 (es) |
| PT (1) | PT3003401T (es) |
| RS (1) | RS60091B1 (es) |
| SA (1) | SA515370233B1 (es) |
| SG (1) | SG11201509856RA (es) |
| SI (1) | SI3003401T1 (es) |
| TN (1) | TN2015000527A1 (es) |
| UA (1) | UA120352C2 (es) |
| WO (1) | WO2014195423A1 (es) |
| ZA (1) | ZA201600027B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| JP2024503908A (ja) | 2021-01-22 | 2024-01-29 | バイエル アクチェンゲゼルシャフト | Ｌｒｒｃ１５抗体およびそのコンジュゲート |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| WO2010126979A1 (en) * | 2009-04-29 | 2010-11-04 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en active Application Filing
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en active Active
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko active IP Right Grant
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh active Active
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja active Active
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715B1/en unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2020
- 2020-03-19 HR HRP20200456TT patent/HRP20200456T1/hr unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| CO2017010618A2 (es) | Anticuerpos contra icos | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| NI201700167A (es) | Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina | |
| CL2016000341A1 (es) | Métodos para tratar la miositis por cuerpos de inclusión esporádica | |
| CO7461144A2 (es) | Tratamiento de una formación subterránea con una composición que incluye un microorganismo o compuesto generado por este | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| EA201591465A1 (ru) | Специфичные участки для модификации антител для получения иммуноконъюгатов | |
| MX2021008755A (es) | Un anticuerpo anti-tau para usarse al tratar una tauopatia. | |
| BR112015032445A2 (pt) | componente semicondutor orgânico | |
| AR096183A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco | |
| BR112015025302A2 (pt) | embalagem para alojar pelo menos um artigo, matriz para formar uma embalagem para alojar pelo menos um artigo, embalagem para alojar pelo menos um artigo, matriz para formar uma embalagem, e método para formar uma embalagem | |
| CY1121304T1 (el) | Μεθοδος καθαρισμου σαπωνινων | |
| CY1120481T1 (el) | Kv1.3 ανταγωνιστες και μεθοδοι χρησης | |
| CL2015003554A1 (es) | Preparado farmacéutico. | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| BR112018010605A2 (pt) | nanoemulsões de bebidas produzidas por processamento de alto cisalhamento | |
| BR112016005207A8 (pt) | métodos e sistema para tratamento de uma formação subterrânea | |
| BR112018000464A2 (pt) | sistema de armazenamento gasoso, métodos para produzir e utilizá-lo | |
| AR097210A1 (es) | Composición para la aglomeración de finos | |
| CO7240413A2 (es) | Composición farmacéutica que comprende fimasartan e hidroclorotiazida | |
| AR095583A1 (es) | Recipiente que tiene un indicador de uso | |
| CL2016001265A1 (es) | Método y sistema para diseñar aviones. | |
| BR112017000022A2 (pt) | nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas |